J. McCrea

发表

Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men

K. Yee, J. McCrea, D. Panebianco, 2018, Clinical Drug Investigation.

A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor

J. McCrea, J. Stone, S. Stoch, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation

A. Tolcher, K. Papadopoulos, A. Patnaik, 2014, Journal of clinical pharmacology.

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

T. Bjornsson, M. Goldberg, J. McCrea, 1995, Clinical pharmacology and therapeutics.

Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics

Michael E. Lassman, X. Chu, J. McCrea, 2021, Clinical pharmacology and therapeutics.

Pharmacokinetics of Ertapenem in Healthy Young Volunteers

S. Waldman, P. Deutsch, H. Greenberg, 2002, Antimicrobial Agents and Chemotherapy.

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin

B. Ma, R. Evers, G. Garrett, 2021, Clinical pharmacology in drug development.

Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved.

A. Besarab, J. McCrea, R. Ross, 1994, ASAIO journal.

Incidence of hypersensitivity and anaphylaxis with sugammadex.

J. McCrea, C. Assaid, W. Herring, 2018, Journal of clinical anesthesia.

Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.

J. McCrea, J. Stone, S. Stoch, 2019, British journal of clinical pharmacology.

Indinavir and Rifabutin Drug Interactions in Healthy Volunteers

S. Waldman, P. Deutsch, W. Kraft, 2004, Journal of clinical pharmacology.

Lovastatin Does Not Affect Oral Glucose Tolerance in Hypercholesterolemic Patients

T. Bjornsson, R. Fruncillo, J. McCrea, 1993, Journal of clinical pharmacology.

Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.

T. Bradstreet, T. Bjornsson, M. Goldberg, 1993, Hypertension.

Next‐day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double‐blind study in healthy elderly subjects

C. Lines, K. Cerchio, J. McCrea, 2009, Human psychopharmacology.

Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography.

D. Webb, D. Newby, M. Goldberg, 2002, British journal of clinical pharmacology.

Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects

J. Butterton, J. McCrea, M. Iwamoto, 2018, Journal of clinical pharmacology.

In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans

T. Prueksaritanont, K. Yee, J. McCrea, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

A mutation in CYP2C9 is responsible for decreased metabolism of losartan

S. Waldman, T. Rushmore, S. Spielberg, 1996 .

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

C. Lines, P. Deutsch, M. Goldberg, 2003, Clinical pharmacology and therapeutics.

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.

S. Waldman, W. Kraft, H. Greenberg, 2003, Clinical therapeutics.

Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study

E. Sellers, J. Wagner, J. McCrea, 2016, Journal of clinical psychopharmacology.

Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects

W. Kraft, K. Yee, J. McCrea, 2019, Clinical Drug Investigation.

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects

W. Kraft, K. Yee, J. McCrea, 2019, Clinical Drug Investigation.

Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.

J. Caro, A. Besarab, A. Erslev, 1992, Journal of the American Society of Nephrology : JASN.

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

A. Tolcher, K. Papadopoulos, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

Single‐ and Multiple‐Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene‐Related Peptide Receptor Antagonist, in Adults

C. Lines, L. Bortel, J. McCrea, 2010, Journal of clinical pharmacology.

PHARMACOKINETICS AND DISPOSITION

G. Alván, J. McCrea, F. Sjöqvist, 1999 .

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

E. Vuurman, A. Vermeeren, S. Jongen, 2016, Psychopharmacology.

Absence of a Pharmacokinetic Interaction between Losartan and Hydrochlorothiazide

L. Tomasko, M. Goldberg, J. McCrea, 1995, Journal of clinical pharmacology.

A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor

J. McCrea, J. Stone, S. Stoch, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects

J. McCrea, D. Panebianco, M. Chakravarthy, 2019, Clinical pharmacology in drug development.

Odanacatib Pharmacokinetics Comparison Between Chinese and Non‐Chinese Postmenopausal Women

Xia Chen, Ji Jiang, P. Hu, 2018, Clinical pharmacology in drug development.

The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women

F. Liu, J. McCrea, J. Stone, 2016, Drug Metabolism and Disposition.

Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants

J. McCrea, D. Panebianco, A. Adedoyin, 2020, Clinical pharmacology in drug development.

Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Subjects

J. McCrea, S. Stoch, K. Furihata, 2022, Clinical pharmacology in drug development.

Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity

S. Waldman, B. Gertz, T. Prueksaritanont, 1999, Journal of clinical pharmacology.

Effect of Fluconazole on Indinavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Patients

P. Deutsch, N. Clumeck, S. De Wit, 1998, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women

J. McCrea, J. Stone, S. Stoch, 2020, Journal of clinical pharmacology.

A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants

Meng Li, J. McCrea, Haiyan Li, 2020, Clinical pharmacology : advances and applications.

Lack of a Pharmacokinetic Interaction between Indinavir and Methadone

P. Deutsch, D. Blazes, J. McCrea, 1999 .

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

C. Lines, M. Goldberg, J. McCrea, 2003, Clinical pharmacology and therapeutics.

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E‐3174

L Gillen, S. Waldman, T. Rushmore, 1999, Clinical pharmacology and therapeutics.

Allergic Reaction to Antipyrine, A Marker of Hepatic Enzyme Activity

J. McCrea, P. Vlasses, M. Rocci, 1989, DICP : the annals of pharmacotherapy.

Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial

J. McCrea, D. Gutstein, C. Assaid, 2018, British journal of anaesthesia.

Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil

W. Kraft, J. McCrea, D. Panebianco, 2019, Journal of clinical pharmacology.

Drug‐Drug Interaction of Letermovir and Atorvastatin in Healthy Participants

Sabrina Fox‐Bosetti, J. McCrea, D. Panebianco, 2022, Clinical pharmacology in drug development.

Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation.

M. Goldberg, J. McCrea, A. S. Yuan, 2000, International journal of clinical pharmacology and therapeutics.

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E‐3174

Susan E. Wilson, P. Deutsch, J. McCrea, 1996, Clinical pharmacology and therapeutics.

Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies

J. McCrea, R. Blanchard, Carolyn R Cho, 2019, Journal of clinical pharmacology.

Tissue Penetration by Ertapenem, a Parenteral Carbapenem Administered Once Daily, in Suction-Induced Skin Blister Fluid in Healthy Young Volunteers

P. Deutsch, M. Guillaume, J. McCrea, 2003, Antimicrobial Agents and Chemotherapy.

Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects

C. Lines, G. Zammit, J. Wagner, 2015, Journal of clinical pharmacology.

Single‐ and Multiple‐Dose Pharmacokinetics of Etoricoxib, a Selective Inhibitor of Cyclooxygenase‐2, in Man

C. Matthews, K. Lasseter, J. McCrea, 2003, Journal of clinical pharmacology.

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.

C. V. Van Leeuwen, E. Vuurman, A. Vermeeren, 2015, Sleep.

Placebo‐ and Amitriptyline‐Controlled Evaluation of Central Nervous System Effects of the NK1 Receptor Antagonist Aprepitant and Intravenous Alcohol Infusion at Pseudo‐Steady State

J. V. van Gerven, D. Tatosian, Diana Selverian, 2013, Journal of clinical pharmacology.

Absorption, Metabolism, Distribution, and Excretion of Letermovir.

X. Chu, P. Kothare, J. McCrea, 2021, Current drug metabolism.

Steady‐state pharmacokinetic interaction of modified‐dose indinavir and rifabutin

C. Flexner, P. Deutsch, Hulin Wu, 2003, Clinical pharmacology and therapeutics.

Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam

W. Kraft, H. Greenberg, Diana Selverian, 2007, Journal of clinical pharmacology.

The Strategic Plan of the American College of Clinical Pharmacy 1998–2000

J. Powell, D. Covey, K. Lake, 1998, Pharmacotherapy.

CPAA_A_224662 1..11

Meng Li, J. McCrea, Haiyan Li, 2020 .

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects

J. Wagner, K. Yee, J. McCrea, 2015, Journal of psychopharmacology.

Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects.

J. McCrea, N. Calder, M. Murphy, 2009, British journal of clinical pharmacology.

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling

J. McCrea, G. Hartmann, Carolyn R Cho, 2023, Clinical and translational science.

The beneficial effects of isradipine on renal hemodynamics in cyclosporine-treated renal transplant recipients.

A. Besarab, J. McCrea, J. Burke, 1993, Transplantation.

Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects.

J. McCrea, N. Calder, J. Boyle, 2009, British journal of clinical pharmacology.

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

E. Vuurman, A. Vermeeren, S. Jongen, 2016, Psychopharmacology.

Transdermal Timolol: β Blockade and Plasma Concentrations After Application for 48 Hours and 7 Days

T. Franz, J. McCrea, P. Vlasses, 1990, Pharmacotherapy.

The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus

W. Kraft, J. Wagner, M. Trucksis, 2012, Cancer Chemotherapy and Pharmacology.

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

A. Tolcher, K. Papadopoulos, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics .

Sabrina Fox‐Bosetti, J. McCrea, D. Panebianco, 2019, International journal of clinical pharmacology and therapeutics.

Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?

A. Besarab, J. McCrea, 1993, ASAIO journal.

Pharmacokinetic interaction between indinavir and rifampin

P. Deutsch, D. Wyss, J. McCrea, 1997 .